583:儿童肿瘤甲基组分析揭示了无细胞DNA中癌症复发的共同特征

D. Buckley, B. Tew, G. Gooden, T. Triche, B. Salhia
{"title":"583:儿童肿瘤甲基组分析揭示了无细胞DNA中癌症复发的共同特征","authors":"D. Buckley, B. Tew, G. Gooden, T. Triche, B. Salhia","doi":"10.1158/1538-7445.AM2021-583","DOIUrl":null,"url":null,"abstract":"Cancer is the second most common cause of death in children aged 1-14 years in the United States, with approximately 11,000 new cases and 1200 deaths annually. Due in part to the rarity and diversity of childhood tumors, a non-invasive diagnostic to identify patients at high risk of recurrence does not exist for patients with pediatric solid cancer. Cell-free (cf)DNA is rapidly becoming the standard for non-invasive screening, diagnosis, treatment and monitoring of human tumors. In particular, cfDNA methylation detection has proven to be a robust platform for “liquid biopsies,” with several important advantages over simple somatic variant detection. Here we present a cfDNA methylation signature derived from a pan-methylome analysis of recurrent pediatric tumors. The methylomes spanned 34 tumor tissue samples, 13 patient-matched adjacent normal, and 16 patient-matched plasma samples from 27 individuals, representing 11 different pediatric tumor types, including 10 neuroblastomas, 4 osteosarcomas and 2 hepatoblastomas. In addition, 13 adjacent normal samples and 15 normal plasma samples were used as DNA methylation controls. These samples were obtained from the Pediatric Oncology Experimental Investigators9 Consortium (POETIC) under informed consent. DNA methylation was analyzed for all samples by whole genome bisulfite sequencing (WGBS). Using consensus DNA methylation calling, we identified a set of 402 differentially methylated regions (DMR) in genomic DNA from tissue, with substantial enrichment of hypomethylated DMRs across a majority of samples. CpGs that were commonly hypomethylated were combined into consensus ‘hotspots.9 In order to discriminate between tumor/normal samples in tissue, we applied supervised machine learning to train a classifier on these 402 features. Mean methylation across these 402 CpG hotspots was significantly (p Citation Format: David N. Buckley, Ben Tew, Gerald Gooden, Timothy Triche, Bodour Salhia. Analysis of solid pediatric tumor methylomes reveals a shared cancer recurrence signature in cell-free DNA [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 583.","PeriodicalId":10518,"journal":{"name":"Clinical Research (Excluding Clinical Trials)","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstract 583: Analysis of solid pediatric tumor methylomes reveals a shared cancer recurrence signature in cell-free DNA\",\"authors\":\"D. Buckley, B. Tew, G. Gooden, T. Triche, B. Salhia\",\"doi\":\"10.1158/1538-7445.AM2021-583\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cancer is the second most common cause of death in children aged 1-14 years in the United States, with approximately 11,000 new cases and 1200 deaths annually. Due in part to the rarity and diversity of childhood tumors, a non-invasive diagnostic to identify patients at high risk of recurrence does not exist for patients with pediatric solid cancer. Cell-free (cf)DNA is rapidly becoming the standard for non-invasive screening, diagnosis, treatment and monitoring of human tumors. In particular, cfDNA methylation detection has proven to be a robust platform for “liquid biopsies,” with several important advantages over simple somatic variant detection. Here we present a cfDNA methylation signature derived from a pan-methylome analysis of recurrent pediatric tumors. The methylomes spanned 34 tumor tissue samples, 13 patient-matched adjacent normal, and 16 patient-matched plasma samples from 27 individuals, representing 11 different pediatric tumor types, including 10 neuroblastomas, 4 osteosarcomas and 2 hepatoblastomas. In addition, 13 adjacent normal samples and 15 normal plasma samples were used as DNA methylation controls. These samples were obtained from the Pediatric Oncology Experimental Investigators9 Consortium (POETIC) under informed consent. DNA methylation was analyzed for all samples by whole genome bisulfite sequencing (WGBS). Using consensus DNA methylation calling, we identified a set of 402 differentially methylated regions (DMR) in genomic DNA from tissue, with substantial enrichment of hypomethylated DMRs across a majority of samples. CpGs that were commonly hypomethylated were combined into consensus ‘hotspots.9 In order to discriminate between tumor/normal samples in tissue, we applied supervised machine learning to train a classifier on these 402 features. Mean methylation across these 402 CpG hotspots was significantly (p Citation Format: David N. Buckley, Ben Tew, Gerald Gooden, Timothy Triche, Bodour Salhia. Analysis of solid pediatric tumor methylomes reveals a shared cancer recurrence signature in cell-free DNA [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 583.\",\"PeriodicalId\":10518,\"journal\":{\"name\":\"Clinical Research (Excluding Clinical Trials)\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Research (Excluding Clinical Trials)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1538-7445.AM2021-583\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research (Excluding Clinical Trials)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1538-7445.AM2021-583","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

癌症是美国1-14岁儿童死亡的第二大常见原因,每年约有1.1万例新病例和1200例死亡。部分由于儿童肿瘤的罕见性和多样性,对于儿童实体癌患者,尚无一种非侵入性诊断方法来识别复发风险高的患者。无细胞DNA (cf)正迅速成为非侵入性筛查、诊断、治疗和监测人类肿瘤的标准。特别是,cfDNA甲基化检测已被证明是一个强大的“液体活检”平台,与简单的体细胞变异检测相比,具有几个重要的优势。在这里,我们提出了一个cfDNA甲基化特征,来自复发性儿科肿瘤的泛甲基组分析。甲基化组跨越了34个肿瘤组织样本,13个患者匹配的邻近正常样本,以及来自27个个体的16个患者匹配的血浆样本,代表了11种不同的儿科肿瘤类型,包括10个神经母细胞瘤,4个骨肉瘤和2个肝母细胞瘤。另外,13例相邻正常样本和15例正常血浆样本作为DNA甲基化对照。这些样本是在知情同意的情况下从儿科肿瘤实验研究者联盟(POETIC)获得的。采用全基因组亚硫酸盐测序(WGBS)分析所有样品的DNA甲基化。使用共识DNA甲基化呼叫,我们在组织基因组DNA中鉴定了402个差异甲基化区域(DMR),在大多数样本中都有大量低甲基化DMR富集。普遍低甲基化的CpGs被合并为共识的热点为了区分组织中的肿瘤/正常样本,我们应用监督式机器学习对这402个特征训练分类器。这402个CpG热点的平均甲基化显著(p引文格式:David N. Buckley, Ben Tew, Gerald Gooden, Timothy Triche, Bodour Salhia)。对儿童肿瘤实体甲基组的分析揭示了无细胞DNA中癌症复发的共同特征[摘要]。见:美国癌症研究协会2021年年会论文集;2021年4月10日至15日和5月17日至21日。费城(PA): AACR;癌症杂志,2021;81(13 -增刊):583。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Abstract 583: Analysis of solid pediatric tumor methylomes reveals a shared cancer recurrence signature in cell-free DNA
Cancer is the second most common cause of death in children aged 1-14 years in the United States, with approximately 11,000 new cases and 1200 deaths annually. Due in part to the rarity and diversity of childhood tumors, a non-invasive diagnostic to identify patients at high risk of recurrence does not exist for patients with pediatric solid cancer. Cell-free (cf)DNA is rapidly becoming the standard for non-invasive screening, diagnosis, treatment and monitoring of human tumors. In particular, cfDNA methylation detection has proven to be a robust platform for “liquid biopsies,” with several important advantages over simple somatic variant detection. Here we present a cfDNA methylation signature derived from a pan-methylome analysis of recurrent pediatric tumors. The methylomes spanned 34 tumor tissue samples, 13 patient-matched adjacent normal, and 16 patient-matched plasma samples from 27 individuals, representing 11 different pediatric tumor types, including 10 neuroblastomas, 4 osteosarcomas and 2 hepatoblastomas. In addition, 13 adjacent normal samples and 15 normal plasma samples were used as DNA methylation controls. These samples were obtained from the Pediatric Oncology Experimental Investigators9 Consortium (POETIC) under informed consent. DNA methylation was analyzed for all samples by whole genome bisulfite sequencing (WGBS). Using consensus DNA methylation calling, we identified a set of 402 differentially methylated regions (DMR) in genomic DNA from tissue, with substantial enrichment of hypomethylated DMRs across a majority of samples. CpGs that were commonly hypomethylated were combined into consensus ‘hotspots.9 In order to discriminate between tumor/normal samples in tissue, we applied supervised machine learning to train a classifier on these 402 features. Mean methylation across these 402 CpG hotspots was significantly (p Citation Format: David N. Buckley, Ben Tew, Gerald Gooden, Timothy Triche, Bodour Salhia. Analysis of solid pediatric tumor methylomes reveals a shared cancer recurrence signature in cell-free DNA [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 583.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Abstract 470: Evaluation of two receptor tyrosine kinase (ROS1) clones by immunohistochemistry Abstract 586: Expression of CD68 on CKpos/CD45poscirculating cells in breast cancer patients: An additional hint supporting the fusion hybrid theory Abstract 401: Comparison of molecular response calculations for prediction of patient outcome Abstract LB061: On-target peripheral and tumor immune microenvironment modulation in patients treated with lacnotuzumab (anti-CSF1, MCS110) + spartalizumab Abstract 550: Cell-free DNA alterations in theAR/enhancer locus measured before AR signaling inhibition portend poor overall survival in metastatic castration resistant prostate cancer patients
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1